Press Releases

Ra Medical Systems Appoints Dan Horwood as General Counsel

CARLSBAD, Calif.--(BUSINESS WIRE)-- Ra Medical Systems, Inc. (NYSE: RMED), a commercial-stage medical device company leveraging its advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases, announced today that it has appointed Dan Horwood as General Counsel, effective immediately. Mr. Horwood brings nearly two decades of corporate and securities experience to Ra Medical and will oversee all aspects of the Company’s legal activities and policies.

“Dan’s deep experience advising publicly listed companies on corporate matters makes him an ideal and timely choice for Ra Medical. We welcome his guidance and counsel as part of our leadership team,” said Dean Irwin, Chief Executive Officer, Ra Medical Systems. “We believe Dan will be an invaluable asset to Ra Medical as our business continues to expand, especially with the continued rollout of our DABRA catheter and laser system across the U.S. and international markets.”

Mr. Horwood joins Ra Medical Systems from Teradata Corporation, where he served as Counsel, Corporate and Transactions, and was responsible for advising on securities compliance issues and M&A activity. Prior to Teradata, he served as Counsel for Wilson Sonsini Goodrich and Rosati, where he advised clients on public offerings, private financing, mergers and acquisitions, securities compliance, public company reporting and corporate governance. Over the years, Mr. Horwood worked at Groupon and BMO Capital Markets in roles of increasing responsibility. Mr. Horwood began his career at the United States Securities and Exchange Commission’s Division of Corporation Finance.

“I am excited to join the Ra Medical team at this pivotal moment in the Company’s development,” said Mr. Horwood. “I look forward to working closely with the executive team at Ra Medical as we continue to expand the Company’s commercial efforts for DABRA.”

Mr. Horwood holds a J.D. from the University of Pennsylvania Law School.

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Ra Medical's future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these words or other similar terms or expressions that concern Ra Medical's future expectations, strategy, plans or intentions. Forward-looking statements in this press release include, but are not limited to, statements regarding the potential expansion of Ra Medical’s business, including the continued rollout of the DABRA catheter and laser system across the U.S. and internationally. Ra Medical's expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of DABRA and Pharos and procedures performed using such devices by physicians, payors, and other third parties; development and acceptance of new products or product enhancements; clinical and statistical verification of the benefits achieved via the use of Ra Medical’s products; the Company’s ability to effectually manage inventory; Ra Medical’s ability to recruit and retain management and key personnel; Ra Medical’s need to comply with complex and evolving laws and regulations; intense and increasing competition and consolidation in Ra Medical’s industry; the impact of rapid technological change; costs and adverse results in any ongoing or future legal proceedings; adverse outcome of regulatory inspections; and the other risks and uncertainties described in Ra Medical’s news releases and filings with the Securities and Exchange Commission. Information on these and additional risks, uncertainties, and other information affecting Ra Medical's business and operating results is contained in Ra Medical’s final prospectus relating to its initial public offering and in its other filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Ra Medical as of the date hereof, and Ra Medical disclaims any obligation to update any forward-looking statements, except as required by law.

Ra Medical investors and others should note that we announce material information to the public about the Company through a variety of means, including our website (www.ramed.com), our investor relations website (https://ir.ramed.com/), press releases, SEC filings, and public conference calls in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.

About Ra Medical Systems

Ra Medical Systems was founded in 2002 and is a commercial-stage medical device company leveraging its advanced excimer laser-based platform for use in the treatment of dermatologic and vascular diseases. DABRA, launched in 2017, is used by physicians as a tool in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. DABRA quickly, photochemically dissolves plaque to the components of its fundamental chemistry. Pharos launched in 2004 and is used as a tool in the treatment of dermatological skin disorders, including psoriasis and vitiligo.

Ra Medical Systems, Inc.
Jeffrey Kraws
760-707-7516

Source: Ra Medical Systems, Inc.